- Conditions
- Ovarian Cancer
- Interventions
- Alpelisib, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • West Palm Beach, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 520
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
- Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Drug Resistant Epilepsy
- Interventions
- Focused ultrasound
- Device
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Ovarian Cancer, Ovarian Diseases, Ovarian Neoplasms
- Interventions
- AGS-8M4, Pegylated liposomal doxorubicin (PLD), gemcitabine, carboplatin
- Biological · Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Epilepsy Intractable
- Interventions
- Direct electrical stimulation
- Device
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Bethesda, Maryland + 7 more
- Conditions
- Food Insecurity, Overweight, Obesity, Cardiometabolic Syndrome
- Interventions
- Weekly Family Food Packages, Family Health Group Sessions
- Other · Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Revere, Massachusetts
- Conditions
- Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus, Human Immunodeficiency Viruses
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- E Coli Infection
- Interventions
- no Intervention
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Torrance, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Drug-Resistant Focal Epilepsy
- Interventions
- Temporal Interference Stimulation, Direct Electrical Stimulation
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Metastatic Castration-resistant Prostatic Neoplasms
- Interventions
- Pasritamig, Placebo, Best Supportive Care (BSC), JNJ-87189401
- Biological · Other · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 55
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 43 more
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Decitabine, Enzalutamide
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Drug-Resistant Epilepsy, Focal-Onset Seizures
- Interventions
- Padsevonil, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Tucson, Arizona • Carlsbad, California + 29 more
- Conditions
- Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
- Interventions
- Ketamine
- Drug
- Lead sponsor
- Minneapolis Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Epilepsy, Seizures, Epileptic
- Interventions
- SPN-817
- Drug
- Lead sponsor
- Supernus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Miami, Florida
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Solid Tumor, Adult, Solid Tumor, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, 11C-YJH08, Optional Tumor Biopsy
- Procedure · Drug
- Lead sponsor
- Rahul Aggarwal
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Solid Cancer
- Interventions
- R-DXd, Paclitaxel, Topotecan, PLD
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 860 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 45
- States / cities
- Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 33 more
- Conditions
- Drug Interactions, Primary Prevention, Cardiometabolic Syndrome, LDL-Cholersterol Lowering, Polypharmacy
- Interventions
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Clostridium Infections, Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-Resistant Enterococci, Carbapenem-Resistant Enterobacteriaceae, Asymptomatic Infections
- Interventions
- Resistant Potato Starch, Maltodextrin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Obesity, Pre-diabetes, Insulin Resistance, Impaired Glucose Tolerance, Impaired Fasting Glucose
- Interventions
- Chromium
- Dietary Supplement
- Lead sponsor
- Griffin Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Derby, Connecticut
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Interventions
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Device · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Treatment Resistant Depression
- Interventions
- VLS-01-203 BU, VLS-01-BU Placebo
- Drug
- Lead sponsor
- atai Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 34
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 30 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Paliperidone, Placebo
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- St. Petersburg, Florida • Indianapolis, Indiana
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2008
- U.S. locations
- 3
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California
- Conditions
- Focal Epilepsy
- Interventions
- BHV-7000
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more